Claudia Robles-Planells

Claudia Robles-Planells

Auto-generated profile, based on publicly available information

Claudia Robles-Planells

The University of Iowa

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
MHMaría José Hevia
María José Hevia
PCPatricio Castro
Patricio Castro
KPKatherine Pinto
Katherine Pinto
MRMauricio Reyna-Jeldes
Mauricio Reyna-Jeldes
FRFelipe Rodríguez-Tirado
Felipe Rodríguez-Tirado
CCClaudio Coddou
Claudio Coddou
Gastric cancer (GC) is the one of the most prevalent cancers and one of the leading causes of cancer-induced deaths. Previously, we found that the expression of purinergic P2Y2 receptor (P2Y2R) is increased in GC samples as compared to adjacent healthy mucosa taken from GC-diagnosed patients. In this work, we studied in detail purinergic signaling in the gastric adenocarcinoma-derived cell lines: AGS, MKN-45, and MKN-74, and compared them to a nontumoral epithelial cell line: GES-1. In GC-derived cells, we detected the expression of several purinergic receptors, and found important differences as compared to GES-1 cells. Functional studies revealed a strong contribution of P2Y2Rs in intracellular calcium increases, elicited by adenosine-triphosphate (ATP), uridine-triphosphate (UTP), and the P2Y2R agonist MRS2768. Responses were preserved in the absence of extracellular calcium and inhibited by P2Y2R antagonists. In GES-1 cells, ATP and UTP induced similar responses and the combination of P2X and P2Y receptor antagonists was able to block them. Proliferation studies showed that ATP regulates AGS and MKN-74 cells in a biphasic manner, increasing cell proliferation at 10–100 μM, but inhibiting at 300 μM ATP. On the other hand, 1–300 μM UTP, a P2Y2R agonist, increased concentration-dependent cell proliferation. The effects of UTP and ATP were prevented by both wide-range and specific purinergic antagonists. In contrast, in GES-1 cells ATP only decreased cell proliferation in a concentration-dependent manner, and UTP had no effect. Notably, the isolated application of purinergic antagonists was sufficient to change the basal proliferation of AGS cells, indicating that nucleotides released by the cells can act as paracrine/autocrine signals. Finally, in tumor-derived biopsies, we found an increase of P2Y2R and a decrease in P2X4R expression; however, we found high variability between seven different biopsies and their respective adjacent healthy gastric mucosa. Even so, we found a correlation between the expression levels of P2Y2R and P2X4R and survival rates of GC patients. Taken together, these results demonstrate the involvement of different purinergic receptors and signaling in GC, and the pattern of expression changes in tumoral cells, and this change likely directs ATP and nucleotide signaling from antiproliferative effects in healthy tissues to proliferative effects in cancer.

29 April 2020 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
CRClaudia Robles-Planells
Claudia Robles-Planells
GSGiselle Sánchez-Guerrero
Giselle Sánchez-Guerrero
CBCarlos Barrera-Avalos
Carlos Barrera-Avalos
SMSilvia Matiacevich
Silvia Matiacevich
LRLeonel E. Rojo
Leonel E. Rojo
CAClaudio Acuña-Castillo
Claudio Acuña-Castillo
Oncolytic virus therapy has been tested against cancer in preclinical models and clinical assays. Current evidence shows that viruses induce cytopathic effects associated with fusogenic protein-mediated syncytium formation and immunogenic cell death of eukaryotic cells. We have previously demonstrated that tumor cell bodies generated from cells expressing the fusogenic protein of the infectious salmon anemia virus (ISAV-F) enhance crosspriming and display prophylactic antitumor activity against melanoma tumors. In this work, we evaluated the effects of the expression of ISAV-F on the B16 melanoma model, both in vitro and in vivo, using chitosan nanoparticles as transfection vehicle. We confirmed that the transfection of B16 tumor cells with chitosan nanoparticles (NP-ISAV) allows the expression of a fusogenically active ISAV-F protein and decreases cell viability because of syncytium formation in vitro. However, the in vivo transfection induces a delay in tumor growth, without inducing changes on the lymphoid populations in the tumor and the spleen. Altogether, our observations show that expression of ISAV fusion protein using chitosan nanoparticles induces cell fusion in melanoma cells and slight antitumor response.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
CRClaudia Robles-Planells
Claudia Robles-Planells
CBCarlos Barrera-Avalos
Carlos Barrera-Avalos
LRLeonel E. Rojo
Leonel E. Rojo
ESEugenio Spencer
Eugenio Spencer
MMMarcelo Cortez-San Martin
Marcelo Cortez-San Martin
CAClaudio Acuña-Castillo
Claudio Acuña-Castillo
Reovirus is known to have an anticancer effect in both the preclinical and clinical assays. Current evidence suggests that the reovirus‐mediated impact on tumor growth depends on the activation of specific antitumor immune responses. A feasible explanation for the oncolytic effects and immune system activation is through the expression of the fusogenic reovirus protein. In this work, we evaluated the in vivo antitumor effects of the expression of fusogenic protein p10 of avian reovirus (ARV‐p10). We used chitosan nanoparticles (CH‐NPs) as a vehicle for the ARV‐p10 DNA in murine B16 melanoma models both in vitro and in vivo. We confirmed that ARV‐p10 delivery through a chitosan‐based formulation (ARV‐p10 CH‐NPs) was capable of inducing cell fusion in cultured melanoma cells, showing a mild cytotoxic effect. Interestingly, intratumor injection of ARV‐p10 CH‐NPs delayed tumor growth, without changing lymphoid populations in the tumor tissue and spleen. The injection of chitosan nanoparticles (CH‐NPs) also delayed tumor growth, suggesting the nanoparticle itself would attack tumor cells. In conclusion, we proved that in vitro ARV‐p10 protein expression using CH‐NPs in murine melanoma cells induces a cytotoxic effect associated with its cell fusion. Further studies are necessary for establishing a protocol for efficient in vivo DNA delivery of fusion proteins to produce an antitumoral effect.

1 April 2016 in Ocean & Coastal Management
Verified
Journal Article
Closed access
LGLaura González-Poblete
Laura González-Poblete
CRClaudia Robles
Claudia Robles
MMMarcelo Cortez San Martín
Marcelo Cortez San Martín

22 October 2019 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
CRClaudia Robles-Planells
Claudia Robles-Planells
SMSofia A. Michelson
Sofia A. Michelson
JMJavier Mena
Javier Mena
DEDaniela Escrig
Daniela Escrig
JRJuan L. Rojas
Juan L. Rojas
CAClaudio Acuña-Castillo
Claudio Acuña-Castillo
Melanoma immunotherapy, specifically the autotransplant of dendritic cells charged with tumors antigens, has shown promising results in clinical trials. The positive clinical effects of this therapy have been associated to increased Th17 response and delayed-type hypersensitivity (DTH) against to tumor antigens. Some synthetic compounds, such as diphenylcyclopropenone (DPCP), are capable of triggering a DTH response in cutaneous malignancies and also to induce clinically relevant effects against melanoma. In this work, we evaluated Litre extract (LExT), a standardized extract of a Chilean stinging plant, Lithraea caustic (Litre). As Litre plant is known to induce DTH, we used a murine B16 melanoma model to compare the topical and intratumor efficacy of LExT with synthetic DTH inducers (DPCP and 2,4-dinitrochlorobenzene [DNCB]). LExt contained mainly long chain catechols and sesquiterpenes. The intratumor injection of LExT induced a significant delay in tumor growth, similarly topical treatment of an established tumor with 0.1% LExT ointment induced a growth delay and even tumor regression in 15% of treated animals. No significant changes were observed on the T-cell populations associated to LExT treatment, and neither DNCB nor DPCP were capable to induce none of the LExT-induced antitumoral effects. Interestingly, our results indicate that LExT induces an antitumor response against melanoma in a mouse model and could bring a new –and affordable- treatment for melanoma in humans.

9 October 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
JMJonathan Morales
Jonathan Morales
CBCarlos Barrera-Avalos
Carlos Barrera-Avalos
CCCarlos Castro
Carlos Castro
SCStephanie Castillo
Stephanie Castillo
CBClaudio Barrientos
Claudio Barrientos
CAClaudio Acuña-Castillo
Claudio Acuña-Castillo
Antigen cross-presentation is a crucial step in the assembly of an antitumor immune response leading to activation of naïve CD8 T cells. This process has been extensively used in clinical trials, in which dendritic cells generated in vitro are loaded with tumor antigens and then auto transplanted to the patients. Recently, the use of autologous transplant of dendritic cells fused with dying tumor cells has demonstrated good results in clinical studies. In this work, we generated a similar process in vivo by treating mice with dead tumor cells (cell bodies) expressing the fusogenic protein of the Infectious salmon anemia virus (ISAV). ISAV fusion protein retains its fusogenic capability when is expressed on mammalian cells in vitro and the cell bodies expressing it facilitates DCs maturation, antigen transfer by APCs, and increase cross-presentation by DCs in vitro. Additionally, we observed in the melanoma model that cell bodies with or without ISAV fusion protein, reduce tumor growth in prophylactic treatment however, only ISAV expressing cell bodies showed an increase CD4 and CD8 cells in spleen. Overall, our results suggest cell bodies could be used as a complement with other type of strategies to amplify anti-tumor immune response.